reported that angiotensin-converting enzyme inhibitors (ACEIs) are recommended for runners with exercise-induced hypertension (EIH), as they exhibit heightened activation of angiotensin II within the renin–angiotensin–aldosterone system (RAAS). This evidence concerns the gene AGT and hypertensive disorder.